Titel: Glitazoner vid typ 2-diabetes - belagda risker, osäker nytta (jämte) Glitazoner är mer än bara blodsockersänkare vid typ 2-diabetes av Åke Sjöholm; Replik: Varningssignaler måste tas på allvar! av Jan Håkansson; Replik: Dra inte alla glitazoner över en kam! av Åke Sjöholm (serie: Medicinsk kontrovers) 2007 nr 43 sid 3198-205

Läs/ladda hem artikeln: Översikt Fullständig referenslista Artikeln i pdf-format (utskriftskvalitet) Sid 3198 Sid 3199 Sid 3200 Sid 3201 Sid 3202 Sid 3203 Sid 3204 Sid 3205 Om Läkartidningens fulltext på Internet Hämta Acrobat Reader

Ämnesord:
Typ 2-diabetes
Hypoglykemiska medel
Tiazolidinedioner
Riskfaktorer
Evidensbaserad medicin























Sök liknande artiklar (ny funktion på försök)

Referenser:
(Håkansson)
1. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403.

2. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001 May 3;344(18):1343-50.

3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53.

4. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854?865.

5. Förebyggande av aterosklerotisk hjärtkärlsjukdom. Läkemedelsverket. Uppsala. 2006

6. Chiasson JL et al. Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance JAMA. 2003;290:486-494.

7. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703?713.

8. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755?1762.

9. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-2016.

10. Colhoun HM, Betteridge DJ, Durrington PN, et al; CARDS, investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-696.

11. Yki-Jarvinen H. Thiazolidindiones. N Engl J Med. 2004;351:1106-18

12. PPAR agonister i behandlingen av typ 2 diabetes. En uppdatering av kunskapsläget. Information från Läkemedelsverket 2005: (16) 2

13. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89

14. Tanne JH FDA places "black box" warning on antidiabetes drugs BMJ 2007;334:1237

15. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death. N Engl J Med 2007;356. DOI: 10.1056/NEJMoa072761

16. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005;294:2581-6.

17. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.

18. Långtidsbehandling med glitazoner ökar risken för frakturer hos kvinnor http://www.lakemedelsverket.se/Tpl/NewsPage____6139.asp

19. Maculaödem vid behandling med rosiglitazon (Avandia, Avandmet) och pioglitazon (Actos)http://www.lakemedelsverket.se/Tpl/NewsPage____1333.aspx

20. Yki-Järvinen H. The PROactive study: some answers, many questions. The Lancet 2006; 366: 1241-42

21. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Dargie H, Komajda M,Gubb J, Biswas N, Jones NP. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol.Diabetologia. 2005 Sep;48(9):1726-35.

22. DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105

23. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme-inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med.2000;342:145-53

24. Nathan DM, Berkwitz M. Trials that matter: Rosiglitazone, Ramipril and the Prevention of Type 2 Diabetes. Ann Intern Med 2007;146:461-3.

25. Montori VM, Isley WL, Guyatt GH Waking up from the DREAM of preventing diabetes with drugsBMJ 2007;334:882-884

26. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD006063. DOI: 10.1002/14651858.CD006063.pub2.


(Sjöholm)
1.Sjöholm Å, Nyström T. Inflammation and the etiology of type 2 diabetes. Diabetes Metab Res Rev. 2006 Jan-Feb;22(1):4-10. Review.
2.Sjöholm Å, Nyström T. Endothelial inflammation in insulin resistance. Lancet. 2005 Feb 12-18;365(9459):610-2. Review.
3.UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998 Sep 12;352(9131):854-65.
4.Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab. 2005;90(1):501-6.
5.Lehtihet M, Welsh N, Berggren PO, Cook GA, Sjöholm Å. Glibenclamide inhibits islet carnitine palmitoyltransferase 1 activity, leading to PKC-dependent insulin exocytosis. Am J Physiol Endocrinol Metab. 2003 Aug;285(2):E438-46.
6.Negroni JA, Lascano EC, del Valle HF. Glibenclamide action on myocardial function and arrhythmia incidence in the healthy and diabetic heart. Cardiovasc Hematol Agents Med Chem. 2007 Jan;5(1):43-53.
7.Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003 Jan 30;348(5):383-93.
8.Waugh J, Keating GM, Plosker GL, Easthope S, Robinson DM. Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs. 2006;66(1):85-109.
9.U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995 Nov;44(11):1249-58.
10.Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006 Dec 7;355(23):2427-43.
11.Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005 Oct 8;366(9493):1279-89.
12.Zeender E, Maedler K, Bosco D, Berney T, Donath MY, Halban PA. Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta. J Clin Endocrinol Metab. 2004 Oct;89(10):5059-66.
13.Zhang F, Sjöholm Å, Zhang Q. Pioglitazone acutely influences glucose-sensitive insulin secretion in normal and diabetic human islets. Biochem Biophys Res Commun. 2006;351:750-5.
14.DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006 Sep 23;368(9541):1096-105.
15.Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 Jun 14;356(24):2457-71.
16.Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med. 2007 Jun 14;356(24):2522-4.
17.McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Safety. 2007 Jul;16(7):711-25.
18.Gottlieb S. Journalistic Malpractice. Wall Street Journal, 070529. http://online.wsj.com/article/SB118040903759116875-search.html (070706)
http://www.diabetolognytt.se/ezin/artiklar/artikelPost.cfm?show=2026&sammaKategori=5
19.http://sv.wikipedia.org/wiki/Nyttig_idiot
20.Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ. Rosiglitazone Evaluated for Cardiovascular Outcomes -- An Interim Analysis. N Engl J Med. 2007 Jun 5; [Epub ahead of print]
21.Pfutzner A, Schneider CA, Forst T. Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. Expert Rev Cardiovasc Ther. 2006 Jul;4(4):445-59.
22.Valentine WJ, Bottomley JM, Palmer AJ, Brandle M, Foos V, Williams R, Dormandy JA, Yates J, Tan MH, Massi-Benedetti M; on behalf of the PROactive Study Group. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. Diabet Med. 2007 Jun 25; [Epub ahead of print]
23.Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007 May 1;49(17):1772-80.
24.Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J; PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007 Mar;38(3):865-73.
25.Rizza R, Henry R, Kahn R. ADA commentary on the results and clinical implications of the PROactive study. Diabetes Care. 2005 Dec;28(12):2965-7.